DEGHOR 120 MG

In the supplied oncology record, Degarelix is associated with Prostate Cancer, particularly in the settings described as Advanced prostate cancer requiring androgen-deprivation therapy. Its pharmacological class is GnRH antagonist. Blocks GnRH receptors in the pituitary, rapidly suppressing LH, FSH and testosterone without an initial testosterone flare. Hormone-pathway suppression is the central therapeutic principle, with treatment selection shaped by the prostate cancer disease state or other hormone-sensitive context described in the indication. The treatment category is recorded as Hormonal / Endocrine Therapy; ADT. Regimen examples include Degarelix monotherapy for androgen deprivation. Rather than implying one universal use, these combinations show the range of contexts in which the medicine may be incorporated. The database places it within endocrine management, where the hormonal environment and disease state are important determinants of clinical use. The clinical significance of the drug is best understood through the disease-specific indication: stage, histology, treatment history, and any molecular or receptor requirement may influence eligibility. Where the same agent is listed for more than one cancer, its role should not be assumed to be interchangeable between diseases. This summary is intentionally non-prescriptive and does not include individualized dosing. Current labeling and relevant disease guidance should be reviewed when the database is used for clinical decision support.